, Volume 115, Issue 1–2, pp 285–288 | Cite as

Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?

  • Gianluigi Tanda
  • Ezio Carboni
  • Roberto Frau
  • Gaetano Di Chiara
Rapid Communication


Drugs differing in their primary mechanism of action but having in common the ability to act as antidepressants such as fluoxetine (10 mg/kg SC), clomipramine (10 mg/kg IP), imipramine (10 mg/kg IP), desipramine (10 mg/kg IP) and (±)8-OHDPAT (0.03 mg/kg SC) increase extracellular concentrations of dopamine in the rat prefrontal cortex but not in the medial nucleus accumbens. Buspirone (1 mg/kg SC) increased dopamine both in the prefrontal cortex and in the nucleus accumbens. Extracellular 5HT was increased by fluoxetine, clomipramine and imipramine but not by desipramine while 8-OHDPAT and buspirone decreased it. These results raise the possibility that the property of stimulating dopamine transmission in the prefrontal cortex has a role in the antidepressant properties of these drugs.

Key words

Antidepressants Dopamine Microdialysis Prefrontal cortex Serotonin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arborelius L, Chergui K, Murase S, Nomikos GG, Backlund Höök B, Chouvet G, Hacksell U, Svensson TH (1993) The 5HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch Pharmacol 347:353–362Google Scholar
  2. Baxter LR, Schwartz JM, Phelps ME, Mazziota JC, Guze BH, Selin CE, Gerner RH, Sumida RM (1989) Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46:243–254Google Scholar
  3. Buchsbaum MS, Wu J, DeLisi LE, Holcomb H, Kessler R, Johnson J, King AC, Hazlett E, Langston K, Post RM (1986) Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. J Affect Disord 10:137–145Google Scholar
  4. Carboni E, Di Chiara G (1989) Serotonin release estimated by transcortical dialysis in freely-moving rats. Neuroscience 32:637–645Google Scholar
  5. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067–1070Google Scholar
  6. Chen J, Paredes W, Van Praag HM, Lowinson JH, Gardner EL (1992) Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10:264–266Google Scholar
  7. Cimino M, Ponzio F, Achilli G, Vantini G, Perego C, Algeri S, Garattini S (1983) Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem Pharmacol 32:1069–1074Google Scholar
  8. De Vry J, Schreiber R, Glaser T, Traber J (1992) Behavioral pharmacology of 5-HT1A agonists: animal models of anxiety and depression. In: Stahl SM et al (eds) Serotonin1A receptors in depression and anxiety. Raven, New York, pp 55–81Google Scholar
  9. Di Chiara G, Tanda G, Frau R, Carboni E (1993) On the preferential release of dopamine in the nucleus accumbens by amphetamine: further evidence obtained by vertically implanted concentric dialysis probes. Psychopharmacology 112:398–402Google Scholar
  10. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME (1992) A functional anatomical study of unipolar depression. J Neurosci 12:3628–3641Google Scholar
  11. Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4:966–977Google Scholar
  12. Imperato A, Di Chiara G (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by transstriatal dialysis. J Neurosci 5:297–306Google Scholar
  13. Jimerson DC (1987) Role of dopamine mechanisms in the affective disorders. In: Melzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 505–511Google Scholar
  14. Lemberger L, Fuller RW, Zerbe RL (1985) Use of specific serotonin uptake inhibitors as antidepressants. Clin Neuropharmacol 8:299–317Google Scholar
  15. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press, New YorkGoogle Scholar
  16. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotaxic atlas of the rat brain, 2nd ed. Plenum, New YorkGoogle Scholar
  17. Thiebot MH, Martin P (1991) Effects of benzodiazepines, 5-HT1A agonists and 5-HT3 antagonists in animal models sensitive to antidepressant drugs. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines. Their comparative pharmacology. Wiley, New York, pp 159–195Google Scholar
  18. Willner P (1983a) Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res Rev 6:211–224Google Scholar
  19. Willner P (1983b) Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res Rev 6:237–246Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Gianluigi Tanda
    • 1
  • Ezio Carboni
    • 1
  • Roberto Frau
    • 1
  • Gaetano Di Chiara
    • 1
  1. 1.Department of ToxicologyUniversity of CagliariCagliariItaly

Personalised recommendations